Sotera Health Company (SHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Sotera Health Company (SHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
SHC - Sotera Health Company
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$22.00
DETAILS
HIGH:
$24.00
LOW:
$18.00
MEDIAN:
$24.00
CONSENSUS:
$22.00
UPSIDE:
40.49%
Stock News
Sotera Health Announces Secondary Offering of Common Stock
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.
Why Broyhill May Be Buying More Sotera Health Shares
Sotera Health offers sterilization and lab testing for healthcare and life sciences clients, supporting global regulatory compliance.
Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
Sotera Health (SHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sotera Health Company (SHC) Surpasses Q1 Earnings and Revenue Estimates
Sotera Health Company (SHC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.14 per share a year ago.
Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Q1 2026 net revenues increased 10.0%, or 6.5% on a co nstant currenc y basis, compared to Q1 2025 Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025 Q1 2026 Adjusted EBITDA ( 1 ) increased 10.5%, or 6.9% on a constant currency basis Q1 2026 Adjusted EPS (1) of $0.18 , an increase of 29% per diluted share Company reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basis Company announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2026. “We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion,” said Chairman and Chief Executive Officer, Michael B.
Sotera Health Announces Leadership Transition
Alton Shader, CEO of Viant Medical®, to become CEO and join the Board of Directors, effective May 26, 2026 Chairman and CEO Michael B. Petras, Jr. will serve as Executive Chairman of the Board of Directors CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced the appointment of Alton Shader to the role of Chief Executive Officer (“CEO”) of the Company, effective May 26, 2026, as part of a planned leadership transition.
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.07 per share a year ago.
Sotera Health Company $SHC Shares Acquired by Cwm LLC
Cwm LLC grew its position in shares of Sotera Health Company (NASDAQ: SHC) by 1,235.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,330 shares of the company's stock after purchasing an additional 64,139 shares during the
Sotera Health Announces First-Quarter 2026 Earnings Release Date
CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m.
All You Need to Know About Sotera Health (SHC) Rating Upgrade to Buy
Sotera Health (SHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Capricorn Fund Managers Ltd Purchases New Shares in Sotera Health Company $SHC
Capricorn Fund Managers Ltd purchased a new position in Sotera Health Company (NASDAQ: SHC) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 449,900 shares of the company's stock, valued at approximately $7,936,000. Sotera Health makes up 1.9% of Capricorn Fund
Sotera Health Company (NASDAQ:SHC) Receives Average Recommendation of “Moderate Buy” from Analysts
Sotera Health Company (NASDAQ: SHC - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target
Sotera Health (SHC) Soars 8.2%: Is Further Upside Left in the Stock?
Sotera Health (SHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop
Sessa Capital increased its Sotera Health holding by 10,630,381 shares in the fourth quarter. The quarter-end position value rose by $206.47 million, reflecting both the share addition and stock price movement.
Sotera Health Shares Down 24% This Year. Is the Stock a Buy as One Investor Reveals Adding $3 Million More?
Inherent Management Corp. purchased 200,050 shares of Sotera Health in the fourth quarter. The quarter-end Sotera Health position value increased by $5.39 million as a result of the purchase.
Sotera Health Company (SHC) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Sotera Health Company (SHC) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today that it has appointed Kenneth D. Krause as a new independent director to its Board of Directors (the “Board”).
Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
MIG Capital sold 2,262,292 shares of Sotera Health worth an estimated $37.41 million in the fourth quarter. Meanwhile, the quarter-end position value decreased by $31.83 million, reflecting both trading activity and share price movements.
Price Targets
Sotera Health price target lowered to $18 from $20 at Barclays
$18.00
(was $15.70)
Barclays
Sotera Health upgraded to Overweight from Neutral at Piper Sandler
$24.00
(was $18.81)
Jason Bednar
·
Piper Sandler
RBC Capital Starts Sotera Health (SHC) at Outperform
$24.00
(was $18.81)
Ryan Halstead
·
RBC Capital
Sotera Health price target raised to $17 from $15 at Piper Sandler
$17.00
(was $16.15)
Piper Sandler
Sotera Health price target raised to $20 from $19 at Barclays
$20.00
(was $16.43)
Barclays
Sotera Health price target raised to $19 from $17 at Barclays
$19.00
(was $16.19)
Barclays
Sotera Health upgraded to Buy from Neutral at Goldman Sachs
$17.00
(was $12.92)
Matthew Sykes
·
Goldman Sachs
Sotera Health (SHC) PT Lowered to $15 at Jefferies
$15.00
(was $12.98)
David Windley
·
Jefferies
Sotera Health (SHC) PT Raised to $18 at Jefferies
$18.00
(was $15.27)
David Windley
·
Jefferies
Sotera Health price target raised to $17 from $14 at Barclays
$17.00
(was $14.22)
Luke Sergott
·
Barclays
Sotera Health (SHC) PT Raised to $14.50 at Jefferies
$14.50
(was $11.98)
David Windley
·
Jefferies
Piper Sandler Starts Sotera Health (SHC) at Neutral
$13.00
(was $10.91)
Jason Bednar
·
Piper Sandler
Sotera Health (SHC) PT Lowered to $17 at RBC Capital
$17.00
(was $10.91)
Sean Dodge
·
RBC Capital
Sotera Health price target lowered to $14 from $19 at Barclays
$14.00
(was $11.62)
Luke Sergott
·
Barclays
Jefferies Upgrades Sotera Health (SHC) to Buy
$15.50
(was $11.94)
David Windley
·
Jefferies
Analyst Upgrades Sotera Health Shares To Overweight, Cites Strong Revenue Growth Outlook
$24.00
(was $18.59)
Matthew Mishan
·
Loop Capital Markets
Sotera Health upgraded to Outperform from Peer Perform at Wolfe Research
$25.00
(was $17.25)
Mike Polark
·
Wolfe Research
Barclays Upgrades Sotera Health (SHC) to Overweight
$22.00
(was $17.25)
Luke Sergott
·
Barclays
Goldman Sachs Maintains Neutral on Sotera Health, Lowers Price Target to $8
$8.00
(was $8.12)
Goldman Sachs
Barclays Downgrades Sotera Health to Underweight, Lowers Price Target to $6
$6.00
(was $7.13)
Barclays